PL378367A1 - Sposób leczenia czynnościowych zaburzeń jelit - Google Patents
Sposób leczenia czynnościowych zaburzeń jelitInfo
- Publication number
- PL378367A1 PL378367A1 PL378367A PL37836704A PL378367A1 PL 378367 A1 PL378367 A1 PL 378367A1 PL 378367 A PL378367 A PL 378367A PL 37836704 A PL37836704 A PL 37836704A PL 378367 A1 PL378367 A1 PL 378367A1
- Authority
- PL
- Poland
- Prior art keywords
- bowel disorders
- functional bowel
- treating functional
- treating
- disorders
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US44007703P | 2003-01-13 | 2003-01-13 | |
US49248003P | 2003-08-04 | 2003-08-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
PL378367A1 true PL378367A1 (pl) | 2006-04-03 |
Family
ID=32718145
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL378367A PL378367A1 (pl) | 2003-01-13 | 2004-01-13 | Sposób leczenia czynnościowych zaburzeń jelit |
Country Status (13)
Country | Link |
---|---|
US (8) | US20040147509A1 (pl) |
EP (2) | EP1558081A4 (pl) |
JP (2) | JP2006516976A (pl) |
KR (1) | KR20050111318A (pl) |
CN (1) | CN100353946C (pl) |
AU (1) | AU2004204825B2 (pl) |
BR (1) | BRPI0406749A (pl) |
CA (1) | CA2512983A1 (pl) |
MX (1) | MXPA05007381A (pl) |
NZ (1) | NZ541008A (pl) |
PL (1) | PL378367A1 (pl) |
WO (1) | WO2004062623A2 (pl) |
ZA (1) | ZA200505817B (pl) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040048874A1 (en) * | 2001-05-22 | 2004-03-11 | Bardsley Hazel Judith | New therapeutic use of 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D]pyrimidine |
GB0216027D0 (en) * | 2002-07-10 | 2002-08-21 | Arachnova Therapeutics Ltd | New therapeutic use |
PL378367A1 (pl) * | 2003-01-13 | 2006-04-03 | Dynogen Pharmaceuticals, Inc. | Sposób leczenia czynnościowych zaburzeń jelit |
DE602004005814T2 (de) * | 2003-01-13 | 2008-01-10 | Dynogen Pharmaceuticals Inc., Waltham | Verfahren zur behandlung von übelkeit, erbrechen, würgereiz oder jede kombination daraus |
CA2519379A1 (en) * | 2003-04-04 | 2004-10-21 | Dynogen Pharmaceuticals, Inc. | Method of treating lower urinary tract disorders |
WO2006080385A1 (ja) * | 2005-01-28 | 2006-08-03 | Astellas Pharma Inc. | 過敏性腸症候群治療薬のスクリーニング方法 |
US20060293309A1 (en) * | 2005-03-28 | 2006-12-28 | Dynogen Pharmaceuticals, Inc. | Method of treating disorders and conditions using peripherally-restricted antagonists and inhibitors |
WO2007000046A1 (en) * | 2005-06-27 | 2007-01-04 | Holburn Biomedical Corporation | Methods for diagnosing functional bowel disease |
EP1906951A4 (en) * | 2005-07-01 | 2009-05-27 | Dynogen Pharmaceuticals Inc | COMPOSITIONS AND METHODS FOR TREATING HYPOMOTILITY OF THE DIGESTIVE SYSTEM AND RELATED DISORDERS |
KR20080068014A (ko) * | 2005-10-07 | 2008-07-22 | 콜로캡스 피와이티 리미티드 | 설사 치료용 제제 |
GB0524668D0 (en) * | 2005-12-02 | 2006-01-11 | Novartis Ag | Organic compounds |
EP2251757B1 (en) * | 2005-12-02 | 2011-11-23 | iRobot Corporation | Coverage robot mobility |
WO2007120445A1 (en) * | 2006-03-31 | 2007-10-25 | Dynogen Pharmaceuticals, Inc. | SOLUBLE SALTS OF THIENO [2,3-d] PYRIMIDINE DERIVATIVES |
TW200838534A (en) * | 2007-02-07 | 2008-10-01 | Astellas Pharma Inc | Treatment for irritable bowel syndrome |
WO2010024306A1 (ja) * | 2008-08-28 | 2010-03-04 | アステラス製薬株式会社 | 過敏性腸症候群の治療方法 |
US9358228B2 (en) * | 2011-10-18 | 2016-06-07 | Helsinn Healthcare Sa | Therapeutic combinations of netupitant and palonosetron |
JOP20130213B1 (ar) | 2012-07-17 | 2021-08-17 | Takeda Pharmaceuticals Co | معارضات لمستقبلht3-5 |
EP2934540B1 (en) | 2012-12-24 | 2023-08-02 | Neurogastrx, Inc. | Methods for treating gi tract disorders |
WO2015200369A1 (en) | 2014-06-24 | 2015-12-30 | Neurogastrx, Inc. | Prodrugs of metopimazine |
CN106795172B (zh) | 2014-09-29 | 2020-07-28 | 武田药品工业株式会社 | 1-(1-甲基-1h-吡唑-4-基)-n-((1r,5s,7s)-9-甲基-3-氧杂-9-氮杂双环[3.3.1]壬-7-基)-1h-吲哚-3-甲酰胺的晶型 |
US10836757B1 (en) | 2020-04-02 | 2020-11-17 | Neurogastrx, Inc. | Polymorphic forms of metopimazine |
WO2022104234A1 (en) * | 2020-11-15 | 2022-05-19 | Castor Trevor P | Methods for assaying and measuring the efficacy of anti-nausea compounds |
CN113412817B (zh) * | 2021-05-31 | 2022-07-12 | 成都中医药大学附属医院 | 提高成模率减少死亡率的ibs-d实验动物模型方法 |
Family Cites Families (79)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US659336A (en) * | 1900-05-25 | 1900-10-09 | Charles H Booth | Pipe-coupling. |
JPS60146891A (ja) * | 1984-01-05 | 1985-08-02 | Mitsubishi Chem Ind Ltd | 〔2,3−d〕チエノピリミジン誘導体およびその塩 |
GB8701022D0 (en) * | 1987-01-19 | 1987-02-18 | Beecham Group Plc | Treatment |
DE3885357T2 (de) * | 1987-06-29 | 1994-03-24 | Duphar Int Res | Anellierte Indolderivate. |
US5007790A (en) | 1989-04-11 | 1991-04-16 | Depomed Systems, Inc. | Sustained-release oral drug dosage form |
US5530008A (en) * | 1989-04-21 | 1996-06-25 | Sandoz Ltd. | Use of 5-HT3 receptor antagonists in treating panic disorders or obsessive compulsive disorders |
US5225407A (en) * | 1990-02-22 | 1993-07-06 | Glaxo Group Limited | 5-HT3 receptor antagonists for the treatment of autism |
EP1022025A3 (en) * | 1991-06-26 | 2002-06-05 | Sepracor, Inc. | Method and compositions for treating emesis nausea and other disorders using optically pure R(+) ondansetron |
JP2699794B2 (ja) * | 1992-03-12 | 1998-01-19 | 三菱化学株式会社 | チエノ〔3,2−b〕ピリジン誘導体 |
US5262428A (en) * | 1992-03-13 | 1993-11-16 | Wake Forest University | Biologically active tropane derivatives |
US5582837A (en) | 1992-03-25 | 1996-12-10 | Depomed, Inc. | Alkyl-substituted cellulose-based sustained-release oral drug dosage forms |
DE69322077T2 (de) | 1992-03-25 | 1999-04-08 | Depomed Inc | Auf hydroxyethylzellulose basierende oralen arzneidosisformen mit verzoegerter wirkstoffabgabe |
US5434174A (en) * | 1992-07-17 | 1995-07-18 | Eli Lilly And Company | Isoxazole derivatives for the treatment of irritable bowel syndrome |
DE4238553A1 (de) * | 1992-11-14 | 1994-05-19 | Kali Chemie Pharma Gmbh | Neue Imidazol-1-yl-Verbindungen enthaltende Arzneimittel |
JPH0616557A (ja) * | 1992-12-21 | 1994-01-25 | Mitsubishi Kasei Corp | 脳機能障害改善剤 |
GB9406857D0 (en) * | 1994-04-07 | 1994-06-01 | Sandoz Ltd | Improvements in or relating to organic compounds |
MY113062A (en) * | 1994-05-10 | 2001-11-30 | The Wellcome Foundation Ltd | Amide derivatives and their therapeutic use |
US5576317A (en) * | 1994-12-09 | 1996-11-19 | Pfizer Inc. | NK-1 receptor antagonists and 5HT3 receptor antagonists for the treatment of emesis |
MY113429A (en) | 1995-02-28 | 2002-02-28 | Univ Temple | Controlled release tablet containing swellable polyethylene oxide |
EP0827402A2 (en) * | 1995-05-17 | 1998-03-11 | Cedars-Sinai Medical Center | Compositions containing fatty acids for improving digestion and absorption in the small intestine |
US7048906B2 (en) * | 1995-05-17 | 2006-05-23 | Cedars-Sinai Medical Center | Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions |
IL122753A (en) * | 1995-07-28 | 2000-10-31 | Dainippon Pharmaceutical Co | (R)-5-bromo-N-(1-ethyl-4-methylhexahydro-1H-1,4-diazepin-6-yl)-2-methoxy-6-methylamino-3-pyridinecarboxamide its preparation and pharmaceutical compositions containing same |
AU702594B2 (en) * | 1995-10-13 | 1999-02-25 | Duphar International Research B.V. | Process for the preparation of enantiomerically pure imidazolyl compounds |
ATE250931T1 (de) * | 1996-02-15 | 2003-10-15 | Janssen Pharmaceutica Nv | Verwendung von 5-ht4 antagonisten zur überwindung der gastrointestinalen beschädigung, die durch inhibitoren der serotonin-wiederaufnahme hervorgerufen werden |
AU3290397A (en) | 1996-06-10 | 1998-01-07 | Depomed, Inc. | Gastric-retentive oral controlled drug delivery system with enhanced retention properties |
US5972389A (en) | 1996-09-19 | 1999-10-26 | Depomed, Inc. | Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter |
SE9701304D0 (sv) * | 1997-04-09 | 1997-04-09 | Astra Pharma Prod | Compounds |
PT975327E (pt) * | 1997-04-18 | 2003-11-28 | Janssen Pharmaceutica Nv | Uso de antagonistas de 5ht3 para estimular a lavagem intestinal |
US6177879B1 (en) * | 1997-05-09 | 2001-01-23 | Honda Giken Kogyo Kabushiki Kaisha | Battery rental system and apparatus |
ES2248908T7 (es) | 1997-06-06 | 2014-11-24 | Depomed, Inc. | Formas de dosificación de fármacos por vía oral y retención gástrica para liberación continuada de fármacos altamente solubles |
US6635280B2 (en) | 1997-06-06 | 2003-10-21 | Depomed, Inc. | Extending the duration of drug release within the stomach during the fed mode |
DE19813661A1 (de) * | 1997-08-01 | 1999-02-04 | Solvay Pharm Gmbh | Gegen Racemisierung stabilisierte pharmazeutische Zubereitungen von Cilansetron |
DE19734444A1 (de) * | 1997-08-08 | 1999-02-11 | Basf Ag | 3-Substituierte 3,4,5,7-Tetrahydro-pyrrolo(3',4':4,5) thieno (2,3-d) pyrimidin-Derivate, ihre Herstellung und Verwendung |
US6156771A (en) * | 1997-08-28 | 2000-12-05 | Rubin; Walter | Method for alleviation of lower gastrointestinal disorders in a human patient |
ATE201598T1 (de) * | 1997-09-16 | 2001-06-15 | Solvay Pharm Gmbh | Verwendung von moxonidin zur behandlung neuropathischer schmerzen |
US6117879A (en) * | 1997-09-16 | 2000-09-12 | Solvay Pharmaceuticals Gmbh | Methods of using moxonidine to inhibit nociceptive pain |
GB9721139D0 (en) * | 1997-10-07 | 1997-12-03 | Glaxo Group Ltd | Medicaments |
US6211171B1 (en) * | 1998-05-19 | 2001-04-03 | Dalhousie University | Use of antidepressants for local analgesia |
US6456458B1 (en) * | 1998-08-08 | 2002-09-24 | Nidec Corporation | Disk-drive motor rotating on a magnetically counterbalanced single hydrodynamic thrust bearing |
US6476078B2 (en) * | 1999-08-11 | 2002-11-05 | Sepracor, Inc. | Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction |
WO2000048597A1 (en) * | 1999-02-18 | 2000-08-24 | Novartis Ag | Systemic use of 5-ht3 receptor antagonists against rheumatic inflammatory processes |
AU3422800A (en) * | 1999-02-18 | 2000-09-04 | Novartis Ag | Use of 5-ht3 receptor antagonists |
US6353005B1 (en) * | 1999-03-02 | 2002-03-05 | Sepracor, Inc. | Method and compositions using (+) norcisapride in combination with proton pump inhibitors or H2 receptor antagonist |
US6362202B1 (en) * | 1999-03-02 | 2002-03-26 | Sepracor Inc. | Methods and compositions using (−) norcisapride in combination with proton pump inhibitors or H2 receptor antagonists |
US6194382B1 (en) * | 1999-03-03 | 2001-02-27 | Albert Einstein College Of Medicine Of Yeshiva University | Method and composition for treating irritable bowel syndrome using low doses of opioid receptor antagonists |
DE19911371A1 (de) * | 1999-03-15 | 2000-09-21 | Solvay Pharm Gmbh | Arzneimittel zur Behandlung von funktionellen Störungen und Erkrankungen der unteren Darmwege, insbesondere von damit einhergehenden abdominalen visceralen Schmerzen |
US6448962B1 (en) | 1999-05-14 | 2002-09-10 | Three-Five Systems, Inc. | Safety timer to protect a display from fault conditions |
DE19929197A1 (de) * | 1999-06-25 | 2000-12-28 | Novosis Pharma Ag | Transdermalsysteme zur Abgabe von 5-HT3-Rezeptor-Antagonisten und ihre Verwendung zur antiemitischen Behandlung |
KR100935277B1 (ko) * | 1999-07-01 | 2010-01-06 | 파마시아 앤드 업존 캄파니 엘엘씨 | 고선택성 노르에피네프린 재흡수 억제제 및 그의 이용 방법 |
GB2355191A (en) * | 1999-10-12 | 2001-04-18 | Laxdale Ltd | Combination formulations for fatigue, head injury and strokes |
EP1242057A2 (en) | 1999-11-02 | 2002-09-25 | DepoMed, Inc. | Pharmacological inducement of the fed mode for enhanced drug administration to the stomach |
AU767812B2 (en) | 2000-02-04 | 2003-11-27 | Depomed, Inc. | Shell-and-core dosage form approaching zero-order drug release |
JP2001243182A (ja) | 2000-02-29 | 2001-09-07 | Nec Corp | サーバシステム及びWebコンテンツとサーバシステムとの連動方法 |
US6488962B1 (en) | 2000-06-20 | 2002-12-03 | Depomed, Inc. | Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms |
US6566369B2 (en) * | 2000-07-26 | 2003-05-20 | Solvay Pharmaceuticals Gmbh | Medicament containing cilansetron for the treatment of non-obstipative male irritable bowel syndrome patients |
US6451808B1 (en) | 2000-10-17 | 2002-09-17 | Depomed, Inc. | Inhibition of emetic effect of metformin with 5-HT3 receptor antagonists |
US6588708B2 (en) * | 2001-01-29 | 2003-07-08 | The Boeing Company | Spacecraft methods and structures for acquiring and determining power-safe attitudes |
US20020107244A1 (en) * | 2001-02-02 | 2002-08-08 | Howard Harry R. | Combination treatment for depression |
GB0112494D0 (en) * | 2001-05-22 | 2001-07-11 | Arachnova Therapeutics Ltd | New therapeutic use |
US20040048874A1 (en) * | 2001-05-22 | 2004-03-11 | Bardsley Hazel Judith | New therapeutic use of 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D]pyrimidine |
GB0216027D0 (en) * | 2002-07-10 | 2002-08-21 | Arachnova Therapeutics Ltd | New therapeutic use |
CA2449009A1 (en) | 2001-05-29 | 2002-12-05 | Depomed Development, Ltd | Method of treating gastroesophageal reflux disease and nocturnal acid breakthrough |
US6568519B2 (en) | 2001-08-10 | 2003-05-27 | Borgwarner, Inc. | Torque limiting chain sprocket assembly |
US6475078B1 (en) * | 2001-10-09 | 2002-11-05 | Norb Borcherding | Air ventilating device |
US20030091630A1 (en) | 2001-10-25 | 2003-05-15 | Jenny Louie-Helm | Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data |
US6723340B2 (en) | 2001-10-25 | 2004-04-20 | Depomed, Inc. | Optimal polymer mixtures for gastric retentive tablets |
TWI312285B (en) | 2001-10-25 | 2009-07-21 | Depomed Inc | Methods of treatment using a gastric retained gabapentin dosage |
CA2409552A1 (en) | 2001-10-25 | 2003-04-25 | Depomed, Inc. | Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract |
EP1438027A1 (en) | 2001-10-25 | 2004-07-21 | DepoMed, Inc. | Methods of treatment using a gastric retained losartan dosage |
US6458795B1 (en) * | 2001-11-15 | 2002-10-01 | University Of Florida | Method and composition for treatment of irritable bowel disease |
ES2281646T3 (es) * | 2002-01-18 | 2007-10-01 | Aryx Therapeutics | Antagonistas del receptor 5-ht3 y procedimientos de utilizacion. |
GB0202265D0 (en) * | 2002-01-31 | 2002-03-20 | Arachnova Therapeutics Ltd | New therapeutic use |
US6682759B2 (en) | 2002-02-01 | 2004-01-27 | Depomed, Inc. | Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs |
US20030203055A1 (en) * | 2002-03-15 | 2003-10-30 | Cypress Bioscience, Inc. | Methods of treating visceral pain syndromes |
US20040032780A1 (en) * | 2002-04-08 | 2004-02-19 | Ehud Langberg | System and method for generating a clock signal in a communication system |
WO2004004734A1 (en) * | 2002-07-10 | 2004-01-15 | Arachnova Therapeutics Ltd. | 4-(2-fluorophenyl)-6-methyl-2(1-piperazinyl)thieno(2,3-d) pyrimidine in the treatment of functional bowel disorder |
CN1678322A (zh) * | 2002-08-29 | 2005-10-05 | 阿瑞科诺沃治疗有限公司 | (4-(2-氟苯基)-6-甲基-2-(1-哌嗪基)噻吩并[2,3-d]嘧啶的新治疗用途 |
DE602004005814T2 (de) * | 2003-01-13 | 2008-01-10 | Dynogen Pharmaceuticals Inc., Waltham | Verfahren zur behandlung von übelkeit, erbrechen, würgereiz oder jede kombination daraus |
PL378367A1 (pl) * | 2003-01-13 | 2006-04-03 | Dynogen Pharmaceuticals, Inc. | Sposób leczenia czynnościowych zaburzeń jelit |
-
2004
- 2004-01-13 PL PL378367A patent/PL378367A1/pl not_active Application Discontinuation
- 2004-01-13 US US10/757,364 patent/US20040147509A1/en not_active Abandoned
- 2004-01-13 CA CA002512983A patent/CA2512983A1/en not_active Abandoned
- 2004-01-13 BR BR0406749-5A patent/BRPI0406749A/pt not_active IP Right Cessation
- 2004-01-13 AU AU2004204825A patent/AU2004204825B2/en not_active Ceased
- 2004-01-13 WO PCT/US2004/000807 patent/WO2004062623A2/en active IP Right Grant
- 2004-01-13 MX MXPA05007381A patent/MXPA05007381A/es not_active Application Discontinuation
- 2004-01-13 EP EP04701811A patent/EP1558081A4/en not_active Withdrawn
- 2004-01-13 JP JP2006500936A patent/JP2006516976A/ja not_active Ceased
- 2004-01-13 EP EP10075488A patent/EP2286817A3/en not_active Withdrawn
- 2004-01-13 KR KR1020057012930A patent/KR20050111318A/ko not_active Application Discontinuation
- 2004-01-13 NZ NZ541008A patent/NZ541008A/en unknown
- 2004-01-13 CN CNB2004800042278A patent/CN100353946C/zh not_active Expired - Fee Related
- 2004-05-03 US US10/838,789 patent/US20040254168A1/en not_active Abandoned
- 2004-05-07 US US10/841,319 patent/US20040259862A1/en not_active Abandoned
- 2004-05-07 US US10/841,318 patent/US20040254170A1/en not_active Abandoned
- 2004-05-07 US US10/841,317 patent/US20040254169A1/en not_active Abandoned
- 2004-06-11 US US10/866,593 patent/US20050032780A1/en not_active Abandoned
-
2005
- 2005-04-29 US US11/119,357 patent/US20050192270A1/en not_active Abandoned
- 2005-07-20 ZA ZA200505817A patent/ZA200505817B/en unknown
-
2006
- 2006-05-26 US US11/441,905 patent/US20060217391A1/en not_active Abandoned
-
2011
- 2011-03-18 JP JP2011061194A patent/JP2011157372A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
US20040254169A1 (en) | 2004-12-16 |
CA2512983A1 (en) | 2004-07-29 |
US20050032780A1 (en) | 2005-02-10 |
BRPI0406749A (pt) | 2005-12-20 |
EP2286817A3 (en) | 2011-06-15 |
US20040259862A1 (en) | 2004-12-23 |
MXPA05007381A (es) | 2006-02-10 |
CN100353946C (zh) | 2007-12-12 |
EP1558081A2 (en) | 2005-08-03 |
JP2006516976A (ja) | 2006-07-13 |
WO2004062623A2 (en) | 2004-07-29 |
CN1750759A (zh) | 2006-03-22 |
AU2004204825A1 (en) | 2004-07-29 |
EP2286817A2 (en) | 2011-02-23 |
NZ541008A (en) | 2007-09-28 |
WO2004062623A3 (en) | 2005-06-09 |
ZA200505817B (en) | 2006-04-26 |
AU2004204825B2 (en) | 2007-07-19 |
JP2011157372A (ja) | 2011-08-18 |
US20060217391A1 (en) | 2006-09-28 |
US20050192270A1 (en) | 2005-09-01 |
US20040254170A1 (en) | 2004-12-16 |
EP1558081A4 (en) | 2006-06-14 |
US20040147509A1 (en) | 2004-07-29 |
KR20050111318A (ko) | 2005-11-24 |
US20040254168A1 (en) | 2004-12-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PL378367A1 (pl) | Sposób leczenia czynnościowych zaburzeń jelit | |
IL240410A0 (en) | Hemolytic disease treatment method | |
EP1635763A4 (en) | METHOD FOR TREATING NEURODEEGENERATIVE ILLNESSES | |
AU2003239489A8 (en) | Method of treating dyslipidemic disorders | |
ZA200508427B (en) | Methods for treating interleuking-6 related diseases | |
IL175351A0 (en) | Methods of treating asthma | |
GB0325192D0 (en) | Method of use | |
EP1651237A4 (en) | METHOD FOR THE TREATMENT OF DERMATOLOGICAL ILLNESSES | |
GB0306309D0 (en) | Method of treatment | |
GB0302572D0 (en) | Method of treatment | |
EP1600511A4 (en) | METHOD FOR THE TREATMENT OF ISCHEMIC ILLNESS | |
PL380068A1 (pl) | Sposób obróbki szlamu | |
EP1493716A4 (en) | METHOD OF WASTE WATER TREATMENT | |
EP1594473A4 (en) | COMPOSITION AND METHOD FOR THE TREATMENT OF AGE-RELATED DISEASES | |
GB0208897D0 (en) | New method of treatment | |
GB0217493D0 (en) | Novel methods of treatment | |
ZA200606071B (en) | Methods of treating asthma | |
GB0221712D0 (en) | Methods of treatment | |
GB0327975D0 (en) | Methods of treatment | |
GB0307544D0 (en) | Treatment method | |
GB0213198D0 (en) | Method of treatment | |
GB0302691D0 (en) | Treatment method | |
GB0302657D0 (en) | Method of treatment | |
GB0311123D0 (en) | Method of treatment | |
GB0312083D0 (en) | Method of treatment |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
REFS | Decisions on refusal to grant patents (taken after the publication of the particulars of the applications) |